Teriparatide and bisphosphonate use in osteoporotic spinal fusion patients: a systematic review and meta-analysis

Sung Huang Laurent Tsai, Ruei Shyuan Chien, Katie Lichter, Raghad Alharthy, Mohammed Ali Alvi, Anshit Goyal, Mohamad Bydon, Tsai Sheng Fu, Tung Yi Lin*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Purpose: Osteoporosis is one of the most common conditions among adults worldwide. It also presents a challenge among patients undergoing spinal surgery. Use of Teriparatide and bisphosphonates in such patients has been shown to improve outcomes after fusion surgery, including successful fusion, decreased risk of instrumentation failure, and patient-reported outcomes. Herein, we performed a systematic review and indirect meta-analysis of available literature on outcomes of fusion surgery after use of bisphosphonates or Teriparatide. Methods: We conducted a comprehensive search of all databases (Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus) to identify studies assessing outcomes of spinal fusion among osteoporotic patients after use of Teriparatide or bisphosphonate. Four authors independently screened electronic search results, and all four authors independently performed study selection. Two authors performed independent data extraction and assessed the studies’ risk of bias assessment using standardized forms of Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) and Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I). Results: Nineteen studies were included in the final analysis. A total of 13 studies evaluated the difference in fusion rate between bisphosphonates and Teriparatide or control group. Fusion rate was higher for bisphosphonates (effect size (ES) 83%, 95% CI 77–89%) compared with Teriparatide (ES 71%, 95% CI 57–85%), with the p value for heterogeneity between groups without statistical significance (p = 0.123). Five studies assessed the impact of using bisphosphonate or Teriparatide on screw loosening. The rate of screw loosening was higher for bisphosphonates (ES 19%, 95% CI 13–25%) compared with Teriparatide (ES 13%, 95% CI 9–16%) without statistical significance (p = 0.52). Conclusion: Our results indicate that while both agents may be associated with positive outcomes, bisphosphonates may be associated with a higher fusion rate, while Teriparatide may be associated with lower screw loosening. The decision to treat with either agent should be tailored individually for each patient keeping in consideration the adverse effect and pharmacokinetic profiles.

Original languageEnglish
Article number158
JournalArchives of Osteoporosis
Issue number1
StatePublished - 01 12 2020

Bibliographical note

Publisher Copyright:
© 2020, International Osteoporosis Foundation and National Osteoporosis Foundation.


  • Bisphosphonate
  • Osteoporosis
  • Spinal fusion
  • Teriparatide


Dive into the research topics of 'Teriparatide and bisphosphonate use in osteoporotic spinal fusion patients: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this